Evidence map›Paper›PMID 39585613›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

Validation of Marburg Virus Inactivation by AVL Buffer.

Todd Cutts, Samantha Kasloff, Jay Krishnan

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Todd CuttsApplied Biosafety Research Program, Public Health Agency of Canada, Winnipeg, MB, Canada. todd.cutts@phac-aspc.gc.ca.
Samantha KasloffApplied Biosafety Research Program, Public Health Agency of Canada, Winnipeg, MB, Canada.
Jay KrishnanSafety and Environmental Services, Public Health Agency of Canada, Winnipeg, MB, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The removal of inactivated Marburg virus (MARV) material from a biosafety level 4 (BSL-4) setting is a critical first step to enable downstream analyses at lower containment levels. The following method presents a highly sensitive approach for efficacy testing of virus inactivation without the loss of a low titer virus that may otherwise be masked by cytotoxic effects of the cells. This protocol outlines the procedure used to validate the inactivation of MARV samples for viral RNA extraction in cell culture, demonstrating accurate contact time needed for exposure, minimal loss of virus titers that may be present in minute quantities, and the removal of toxic elements to cells.

Indexed as

MarburgvirusVirus InactivationAnimalsBuffersCell LineContainment of BiohazardsHumansMarburg Virus DiseaseRNA, ViralBuffersRNA, ViralAmicon filtration columnAVLFilovirusInactivation testingMARV

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.